VivoSeq
Other

Lymphoproliferative Disorder

13

Pipeline Programs↗

3

Active Trials↗

7

Companies Involved↗

Lymphoproliferative Disorder is an emerging landscape with 13 programs across 7 companies. The most active players are Eli Lilly, Avyxa, Ainos, Inc. (f/k/a Amarillo Biosciences Inc..

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

0/100

Mech. Concentration

11/100

Completion Rate

50/100

Attrition Rate

29/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

2 programs

Phase 2A

Avyxa

1 program

Phase 2A

Ainos, Inc. (f/k/a Amarillo Biosciences Inc.

1 program

Phase 2Roche logo

Roche

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2E

Eastern Cooperative Oncology Group

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

85%

Small molecule

11 of 13 classified programs — the dominant modality here.

15%ALL OTHERSMonoclonal antibody18%Protein / enzyme18%

Small molecule leads; the ring shows all 13 classified programs, each share of the total. Modality classified for 100% of 13 pipeline programs.

Analysis

Trial Status

7

clinical trials

Terminated2 · 29%
Recruiting2 · 29%
Completed2 · 29%
Active, not recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
Recruiting·—·Phase 2·NCT06954805·30 enrolled
Study of the Immunopathogenesis, Natural History, and Genetics of Autoimmune Lymphoproliferative Syndrome (ALPS) Associated With an Expansion of CD4-8-/TCR Alpha/Beta+ T Cells
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001350·1,200 enrolled
Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease With Laboratory and Clinical Correlates of Disease Activity
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT00092222·75 enrolled
Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT
Completed·MMemorial Sloan Kettering Cancer Center·N/A·NCT00648037·26 enrolled
Monoclonal Antibody Therapy in Treating Patients With Lymphoproliferative Disorder Associated With Immunosuppression Therapy
Completed·SStanford University·Phase 2·NCT00003716·25 enrolled
Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)
Terminated·—·Phase 2·NCT01458548·70 enrolled
Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder
Terminated·—·Phase 2·NCT04337827·6 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)